Cocrystal Pharma Registers 5.7M Shares for Resale; Influenza Study Faces Delays

TL;DR

**COCP is registering millions of shares for resale, signaling potential dilution while its key influenza trial hits a snag, making it a risky bet.**

AI Summary

Cocrystal Pharma, Inc. (COCP) is a clinical-stage biotechnology company focused on developing novel antiviral therapeutics. The company is not selling any securities in this S-1 filing, but rather registering 5,736,773 shares of common stock for resale by existing selling stockholders, issuable upon the exercise of outstanding warrants. These warrants include 5,529,420 issued to accredited investors and 207,353 issued to a placement agent in a prior private placement. COCP will not receive any proceeds from these sales. The company's lead candidate, CC-42344, a novel PB2 inhibitor for influenza A, is currently in a Phase 2a human challenge study. Enrollment for this study was completed with 78 subjects in May 2024, but an extension was announced in December 2024 due to an unexpectedly low influenza infection rate among participants, potentially incurring substantial additional costs. CC-42344 has demonstrated favorable safety and tolerability in the Phase 2a study to date, with no serious adverse events. In May 2025, in vitro data showed CC-42344 is highly potent against the H5N1 avian influenza A strain (EC50, 0.003 µM). The company also has CDI-988, a novel protease inhibitor, in development as an oral pan-viral treatment for noroviruses and coronaviruses.

Why It Matters

This S-1 filing is crucial for investors as it signals potential dilution from the resale of 5,736,773 shares by existing stockholders, even though Cocrystal Pharma itself won't receive direct proceeds. The delay in the Phase 2a study for CC-42344 due to low infection rates could impact the company's timeline to market and increase R&D expenses, a significant concern for a clinical-stage biotech. Competitively, the in vitro efficacy of CC-42344 against H5N1 avian flu is a positive, but the company faces intense competition from larger pharmaceutical firms with more advanced antiviral pipelines and greater financial resources. Employees and customers will be watching for successful clinical trial outcomes to validate the company's drug discovery platform and secure its long-term viability.

Risk Assessment

Risk Level: high — The risk level is high due to the significant uncertainty surrounding the Phase 2a study for CC-42344, where an 'unexpectedly low influenza infection' rate necessitated an enrollment extension, potentially incurring 'substantial additional costs.' Furthermore, the registration of 5,736,773 shares for resale by existing stockholders, without the company receiving any proceeds, presents a substantial overhang and potential for dilution for current shareholders.

Analyst Insight

Investors should exercise extreme caution and consider the potential for significant dilution from the 5,736,773 shares being registered for resale. Monitor closely for updates on the CC-42344 Phase 2a study, as further delays or negative results could severely impact the stock. Given the high-risk profile, a wait-and-see approach is advisable.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

+0%

Key Numbers

• 5,736,773 — Shares of Common Stock (Number of shares registered for resale by selling stockholders, representing potential dilution.)
• $0.001 — Par Value per Share (Par value of Cocrystal Pharma's common stock.)
• $1.27 — Reported Sale Price (Closing price of COCP common stock on The Nasdaq Capital Market on September 18, 2025.)
• 78 — Subjects Enrolled (Number of subjects enrolled in the Phase 2a study for oral CC-42344 by May 2024.)
• 0.003 µM — EC50 (In vitro efficacy of CC-42344 against H5N1 avian influenza A strain, demonstrating high potency.)

Key Players & Entities

• Cocrystal Pharma, Inc. (company) — Registrant in S-1 filing
• James Martin (person) — Agent for service
• Michael D. Harris, Esq. (person) — Legal counsel from Nason, Yeager, Gerson, Harris & Fumero, P.A.
• Roger Kornberg (person) — Chief Scientist and Chairman of Scientific Advisory Board and Board of Directors, Nobel Prize recipient
• United Kingdom Medicines and Healthcare Products Regulatory Agency (MHRA) (regulator) — Authorized Phase 2a study for CC-42344
• The Nasdaq Capital Market (company) — Stock exchange where COCP is listed
• Securities and Exchange Commission (SEC) (regulator) — Regulatory body for S-1 filing
• Nason, Yeager, Gerson, Harris & Fumero, P.A. (company) — Legal firm providing counsel

FAQ

Risk Factors

• Reliance on Clinical Trial Success [high — operational]: The company's success is heavily dependent on the successful development and commercialization of its drug candidates, particularly CC-42344. The Phase 2a study for CC-42344 experienced an extension due to an unexpectedly low influenza infection rate, which could lead to substantial additional costs and delays.
• Need for Future Financing [high — financial]: As a clinical-stage biotechnology company, Cocrystal Pharma has a history of losses and expects to incur significant expenses in the future for research, development, and potential commercialization. The company will likely require substantial additional funding, which may not be available on favorable terms or at all.
• Regulatory Approval Uncertainty [high — regulatory]: The development and commercialization of pharmaceutical products are subject to stringent regulatory review and approval processes by agencies like the FDA. There is no guarantee that any of Cocrystal Pharma's drug candidates will receive regulatory approval.
• Competition in Antiviral Market [medium — market]: The antiviral market is highly competitive, with numerous established pharmaceutical companies and emerging biotechs developing treatments for influenza, coronaviruses, and noroviruses. Cocrystal Pharma faces competition from companies with greater resources and established market presence.
• Dependence on Key Personnel [medium — operational]: The company's success relies on its ability to attract and retain highly qualified scientific and management personnel. The loss of key individuals, such as Dr. Roger Kornberg, could significantly impact its research and development efforts.

Industry Context

Cocrystal Pharma operates in the highly competitive and rapidly evolving antiviral therapeutics market. The industry is characterized by significant R&D investment, long development cycles, and stringent regulatory hurdles. Key trends include the ongoing threat of novel viral outbreaks (like COVID-19), the emergence of drug-resistant strains, and a growing demand for oral, convenient treatments.

Regulatory Implications

The company's drug candidates must undergo rigorous clinical trials and obtain approval from regulatory bodies such as the FDA. Delays or failures in clinical trials or the inability to secure regulatory approval represent significant risks. The S-1 filing itself is a regulatory document, and its accuracy and completeness are subject to SEC oversight.

What Investors Should Do

1. Monitor CC-42344 clinical trial progress and cost implications.
2. Assess the company's cash runway and future financing needs.
3. Evaluate the competitive landscape for influenza and pan-viral treatments.
4. Review the scientific rationale and in vitro data for CC-42344 and CDI-988.

Key Dates

• 2024-05: Phase 2a study enrollment completed — Indicates progress in clinical development of CC-42344, with 78 subjects enrolled.
• 2024-12: Phase 2a study extension announced — Highlights potential challenges in trial execution due to low infection rates, possibly increasing costs and delaying timelines.
• 2025-05: In vitro data for CC-42344 against H5N1 released — Demonstrates high potency (EC50, 0.003 µM) against a significant avian influenza strain, supporting the drug's potential.

Glossary

PB2 inhibitor

A type of drug that blocks the function of the PB2 protein, which is essential for the replication of influenza A viruses. (CC-42344, the company's lead candidate, is a PB2 inhibitor for influenza A.)

EC50

The effective concentration 50%, which is the concentration of a drug that produces 50% of its maximal effect in vitro. (A low EC50 value, like 0.003 µM for CC-42344 against H5N1, indicates high potency.)

Structure-based drug design

A method of designing drugs by studying the three-dimensional structure of target molecules (like viral proteins) to create compounds that fit and inhibit them. (Cocrystal Pharma uses this proprietary platform, guided by Nobel Prize winner Dr. Roger Kornberg, to develop its antiviral candidates.)

RNA viruses

Viruses that use ribonucleic acid (RNA) as their genetic material. Many significant human pathogens are RNA viruses. (Cocrystal Pharma focuses on developing antivirals for RNA viruses like coronaviruses, influenza viruses, and noroviruses.)

Protease inhibitor

A type of drug that blocks the action of proteases, enzymes that are crucial for viral replication and maturation. (CDI-988, another candidate from Cocrystal Pharma, is a protease inhibitor targeting noroviruses and coronaviruses.)

Year-Over-Year Comparison

This S-1 filing is primarily for the resale of existing shares by selling stockholders and does not represent a new capital raise. Therefore, direct comparisons of financial metrics like revenue growth or net income to a prior period are not applicable in the context of this specific filing. The focus remains on the clinical development progress of CC-42344 and the potential dilution from the resale of shares.

Key Financial Figures

• $0.001 — 3 shares of our common stock, par value $0.001 per share, issuable upon exercise of ou
• $1.27 — stock on The Nasdaq Capital Market was $1.27 per share. Investing in our securitie

Filing Documents

• forms-1.htm (S-1) — 378KB
• ex5-1.htm (EX-5.1) — 13KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 62KB
• 0001493152-25-014266.txt ( ) — 589KB
• ex107_htm.xml (XML) — 9KB

USE OF PROCEEDS

USE OF PROCEEDS 14 SELLING STOCKHOLDERS 14 PLAN OF DISTRIBUTION 17 LEGAL MATTERS 21 EXPERTS 21 INCORPORATION BY REFERENCE 21 DISCLOSURE OF COMMISSION POSITION ON INDEMNIFICATION FOR SECURITIES ACT LIABILITIES 22 WHERE YOU CAN FIND MORE INFORMATION 22 i ABOUT THIS PROSPECTUS This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under “Selling Stockholders” beginning on page 14, of up to 5,736,773 shares of our common stock issuable upon exercise of the Warrants. We are not selling any securities under this prospectus, and we will not receive any proceeds from the sale of shares of our common stock by the selling stockholders under this prospectus. This prospectus is part of a registration statement on Form S-1 that we have filed with the Securities and Exchange Commission (the “SEC”). This prospectus omits some of the information contained in the registration statement, and we refer you to the full registration statement for further information about us and the securities being offered by the selling stockholders under this prospectus. Before making an investment decision, you should read, in addition to this prospectus and the registration statement, any documents that we incorporate by reference in this prospectus, as referred to under “Incorporation By Reference” beginning on page 21, and the information under “Where You Can Find More Information” beginning on page 22. Any statement contained in the prospectus concerning the provisions of any document filed as an exhibit to the registration statement or otherwise filed with the SEC is not necessarily complete, and in each instance reference is made to the copy of the document filed. You should review the complete document to evaluate these statements. Further, you should not assume that the information in this prospectus or any documents incorporated by reference herein is acc

Business

Business Cocrystal is a clinical-stage biotechnology company seeking to discover and develop novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. We employ unique structure-based technologies and Nobel Prize winning expertise to create antiviral drugs. These technologies are designed to efficiently deliver small molecule therapeutics that are safe, effective, and convenient to administer. We have identified promising discovery, preclinical and clinical stage antiviral compounds for unmet medical needs caused by coronavirus, influenza virus and norovirus. The Company operates in one segment. Management uses cash flows as the primary measure to manage its business and does not segment its business for internal reporting or decision-making. Cocrystal Technology We are developing antiviral therapeutics that inhibit the essential viral replication the function of RNA viruses causing acute and chronic viral diseases. Our goals include treating influenza viruses, norovirus, and coronavirus, infections by discovering and developing drug candidates targeting the viral replication process. In the case of coronavirus antiviral therapeutics, we target replication enzymes and proteases that are required for the viral replication and transcription. To discover and design these inhibitors, we use a proprietary platform comprising computational chemistry, medicinal chemistry, X-ray crystallography and our extensive know-how. We determine the structures of cocrystals containing the inhibitors bound to the enzyme or protein to guide our structure-based drug design. We also use advanced computational methods to screen and design product candidates using proprietary cocrystal structural information. In designing the candidates, we seek to anticipate and avert potential viral mutations leading to resistance. By designing and selecting drug candidates that interrupt the viral replication process and also have specific binding characteristics, we s

View Full Filing

View this S-1 filing on SEC EDGAR